Beverly Green, MD, MPH, is a physician scientist known for pioneering work in preventive and evidence-based medicine. With a goal of improving systems of care, she designs and evaluates programs that make effective treatment easier for patients to follow through with — and easier for providers to deliver.
Dr. Green’s research has a strong public health emphasis, targeting conditions that impact large proportions of the population — such as cardiovascular disease, cancer, and obesity — with an emphasis on leveraging technologies and systems-based care.
In 2022, Dr. Green published the results of the BP-CHECK study, which compared the accuracy and acceptability of ways to diagnose high blood pressure. With a $2.8 million award from PCORI (the Patient-Centered Outcomes Research Institute), the study compared blood pressures taken in clinic, at home, and at validated blood pressure kiosks to the 24-hour blood pressure test that is currently considered the gold standard for diagnosing hypertension. Blood pressures taken at home were the most accurate and most preferred method for diagnosing hypertension. She is working with Kaiser Permanente Washington on their efforts to integrate home blood pressure monitoring into clinical care.
Dr. Green is also leading a National Cancer Institute study that is evaluating the effectiveness of home-based human papilloma virus (HPV) kits to increase completion of cervical cancer screening.
Dr. Green’s previous research has shown that:
She is a core member of the Alliance for Reducing Cancer, Northwest, a collaborative team of cancer prevention and control experts and community stakeholders whose mission is to evaluate and respond to gaps in the Guide to Community Preventive Services (the Community Guide). She serves on the steering committee of the National Colorectal Cancer Round Table (an elected position) and is on the U.S. Validated Blood Pressure Device Review Committee.
Dr. Green was honored by Kaiser Permanente Washington in 1999 for her contributions to clinical quality improvement and was a finalist for the organization's 2004 Lifetime Achievement Award. She was an associate editor for the American Journal of Preventive Medicine from 2009 to 2014, and she is an editorial board member of the Journal of the American Board of Family Practice. She is a fellow of the American Heart Association, an honor given for contributions to the field.
Dr. Green is a clinical professor at the University of Washington School of Medicine, Department of Family Medicine, and a professor at the Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health Systems Science.
Winer RL, Lin J, Anderson ML, Tiro JA, Green BB, Gao H, Meenan RT, Hansen K, Sparks A, Buist DSM. Strategies to increase cervical cancer screening with mailed human papillomavirus self-sampling kits: A randomized clinical trial. JAMA. 2023 Nov 28;330(20):1971-1981. doi: 10.1001/jama.2023.21471. PubMed
Liu PH, Nair RG, Skinner CS, Murphy CC, Kim EJ, Ortiz C, Wang L, Hu E, Lykken JM, Levin TR, Green BB, Hahn EE, Santini N, Halm EA. Unsatisfactory fecal immunochemical tests for colorectal cancer screening: prevalence, reasons, and subsequent testing. Cancer Epidemiol Biomarkers Prev. 2023 Nov 15:OF1-OF9. doi: 10.1158/1055-9965.EPI-23-0507. Online ahead of print. PubMed
Green BB, Anderson ML, Ehrlich K, Hall YN, Hansell LD, Hsu C, Margolis KL, McClure JB, Munson S, Thompson MJ. Is hypertension diagnostic testing and diagnosis associated with psychological distress? Am J Hypertens. 2023 Sep 9:hpad083. doi: 10.1093/ajh/hpad083. Online ahead of print. PubMed
Dalmat RR, Ziebell RA, Kamineni A, Phipps AI, Weiss NS, Breslau ES, Burnett-Hartman AN, Corley DA, Doria-Rose VP, Green BB, Halm EA, Levin TR, Schottinger JE, Chubak J. Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds. Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1382-1390. doi: 10.1158/1055-9965.EPI-23-0265. PubMed
Meenan RT, Troja C, Buist DSM, Tiro JA, Lin J, Anderson ML, Gao H, Green BB, Winer RL. Economic evaluation of mailed home-based human papillomavirus self-sampling kits for cervical cancer screening. JAMA Netw Open. 2023 Mar 1;6(3):e234052. doi: 10.1001/jamanetworkopen.2023.4052. PubMed
New study builds on findings that home tests improve screening rates.
Bev Green, doctor and scientist, has tips for monitoring your blood pressure without leaving your house.
Research finds that mailing HPV test kits directly to patients increases cervical cancer screening rates.
AARP, June 3, 2024
How KPWHRI is contributing to better cancer screening and better outcomes for patients.